Methodology for a correlate of protection for group B Streptococcus: Report from the Bill & Melinda Gates Foundation workshop held on 10 and 11 February 2021

Peter B. Gilbert, Richard Isbrucker, Nick Andrews, David Goldblatt, Paul T. Heath, Alane Izu, Shabir A. Madhi, Lawrence Moulton, Stephanie J. Schrag, Nong Shang, George Siber, Ajoke Sobanjo-ter Meulen

Research output: Contribution to journalArticlepeer-review


Worldwide, childhood mortality has declined significantly, with improvements in hygiene and vaccinations against common childhood illnesses, yet newborn mortality remains high. Group B Streptococcus (GBS) disease significantly contributes to newborn mortality and is the leading cause of meningitis in infants. Many years of research have demonstrated the potential for maternal vaccination against GBS to confer protection to the infant, and at least three vaccine candidates are currently undergoing clinical trials. Given the relatively low disease incidence, any clinical vaccine efficacy study would need to include at least 40,000 to 60,000 participants. Therefore, a path to vaccine licensure based on a correlate of protection (CoP) would be the preferred route, with post-approval effectiveness studies demonstrating vaccine impact on reduction of disease burden likely to be required as part of conditional marketing approval. This workshop, hosted by the Bill & Melinda Gates Foundation on 10 and 11 February 2021, discussed considerations and potential statistical methodologies for establishing a CoP for GBS disease. Consensus was reached that an antibody marker with global threshold predictive of a high level of vaccine protection would be most beneficial for licensure assessments. IgG binding antibody in cord blood would likely serve as the CoP, with additional studies needed to confirm a high correlation with functional antibody and to demonstrate comparable kinetics of natural versus vaccine-induced antibody. Common analyses of ongoing seroepidemiological studies include estimation of absolute and relative disease risk as a function of infant antibody concentration, with adjustment for confounders of the impact of antibody concentration on infant GBS disease including gestational age and maternal age. Estimation of an antibody concentration threshold indicative of high protection should build in margin for uncertainties from sources including unmeasured confounders, imperfect causal mediation, and variability in point and confidence interval estimates across regions and/or serotypes.

Original languageEnglish (US)
Pages (from-to)4283-4291
Number of pages9
Issue number32
StatePublished - Jul 30 2022


  • Correlate of protection
  • Group B Streptococcus
  • Licensure
  • Statistical analysis
  • Vaccine development

ASJC Scopus subject areas

  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases
  • Molecular Medicine
  • Immunology and Microbiology(all)


Dive into the research topics of 'Methodology for a correlate of protection for group B Streptococcus: Report from the Bill & Melinda Gates Foundation workshop held on 10 and 11 February 2021'. Together they form a unique fingerprint.

Cite this